S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
S&P 500   5,249.78 (+0.02%)
DOW   39,754.40 (-0.01%)
QQQ   444.67 (-0.04%)
AAPL   171.32 (-1.15%)
MSFT   421.14 (-0.07%)
META   490.57 (-0.67%)
GOOGL   150.71 (-0.11%)
AMZN   181.19 (+0.76%)
TSLA   176.61 (-1.79%)
NVDA   910.28 (+0.86%)
NIO   4.71 (+0.86%)
AMD   181.70 (+1.17%)
BABA   72.32 (+1.02%)
T   17.52 (-0.17%)
F   13.22 (+1.23%)
MU   117.62 (-1.28%)
CGC   9.02 (-5.55%)
GE   177.12 (-1.67%)
DIS   123.09 (+1.74%)
AMC   3.82 (-11.98%)
PFE   27.85 (+0.25%)
PYPL   66.66 (+0.14%)
XOM   115.30 (+0.29%)
NASDAQ:ONTX

Onconova Therapeutics (ONTX) Stock Price, News & Analysis

$1.05
+0.08 (+8.25%)
(As of 10:10 AM ET)
Today's Range
$0.99
$1.05
50-Day Range
$0.67
$0.97
52-Week Range
$0.55
$1.45
Volume
45,168 shs
Average Volume
73,836 shs
Market Capitalization
$22.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Onconova Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,000.0% Upside
$11.00 Price Target
Short Interest
Healthy
0.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Onconova Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.36 out of 5 stars

Medical Sector

508th out of 939 stocks

Pharmaceutical Preparations Industry

240th out of 434 stocks

ONTX stock logo

About Onconova Therapeutics Stock (NASDAQ:ONTX)

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX Stock Price History

ONTX Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Onconova Therapeutics Inc (ONTX)
Onconova Therapeutics, Inc. (ONTX)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+1,034.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,960,000.00
Net Margins
-8,930.97%
Pretax Margin
-8,930.97%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$1.35 per share

Miscellaneous

Free Float
20,310,000
Market Cap
$20.37 million
Optionable
Optionable
Beta
1.34
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

ONTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

What is Onconova Therapeutics' stock price target for 2024?

1 brokerages have issued 1-year price targets for Onconova Therapeutics' stock. Their ONTX share price targets range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,000.0% from the stock's current price.
View analysts price targets for ONTX
or view top-rated stocks among Wall Street analysts.

How have ONTX shares performed in 2024?

Onconova Therapeutics' stock was trading at $0.7456 at the beginning of the year. Since then, ONTX stock has increased by 34.1% and is now trading at $1.00.
View the best growth stocks for 2024 here
.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 20,700 shares, a decrease of 58.8% from the February 29th total of 50,300 shares. Based on an average daily volume of 75,900 shares, the days-to-cover ratio is presently 0.3 days.
View Onconova Therapeutics' Short Interest
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the prior year, the firm posted ($0.45) EPS.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, James J Marino and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners